Drug research

Pimavanserin

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Nuplazid

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseNCT03623321	ACAD	Phase 3	Completed	2023-05-05Actual
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative DiseaseNCT03575052	ACAD	Phase 3	Completed	2022-05-06Actual
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderNCT05523895	ACAD	Phase 2, Phase 3	Completed	2024-09-27Actual
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum DisorderNCT05555615	ACAD	Phase 2, Phase 3	Terminated	2025-02-14Actual
Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586	ACAD	Phase 3	Terminated	2024-04-30Actual
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of SchizophreniaNCT04531982	ACAD	Phase 3	Completed	2024-01-25Actual

ACADCompletedPrimary completion: 2023-05-05 · Actual

Trial details

ACADCompletedPrimary completion: 2022-05-06 · Actual

Trial details

ACADCompletedPrimary completion: 2024-09-27 · Actual

Trial details

ACADTerminatedPrimary completion: 2025-02-14 · Actual

Trial details

ACADTerminatedPrimary completion: 2024-04-30 · Actual

Trial details

ACADCompletedPrimary completion: 2024-01-25 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.